Turkish Journal of Medical Sciences
Volume 46

Number 6

Article 37

1-1-2016

The factors affecting survival in patients with bronchiectasis
FATMA ÇİFTCİ
ELİF ŞEN
SEVGİ BEHİYE SARYAL
ZEYNEP PINAR ÖNEN
BANU GÜLBAY

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ÇİFTCİ, FATMA; ŞEN, ELİF; SARYAL, SEVGİ BEHİYE; ÖNEN, ZEYNEP PINAR; GÜLBAY, BANU; YILDIZ,
ÖZNUR; ACICAN, TURAN; and KARABIYIKOĞLU, GÜLSEREN (2016) "The factors affecting survival in
patients with bronchiectasis," Turkish Journal of Medical Sciences: Vol. 46: No. 6, Article 37.
https://doi.org/10.3906/sag-1511-137
Available at: https://journals.tubitak.gov.tr/medical/vol46/iss6/37

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

The factors affecting survival in patients with bronchiectasis
Authors
FATMA ÇİFTCİ, ELİF ŞEN, SEVGİ BEHİYE SARYAL, ZEYNEP PINAR ÖNEN, BANU GÜLBAY, ÖZNUR YILDIZ,
TURAN ACICAN, and GÜLSEREN KARABIYIKOĞLU

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol46/iss6/37

Turkish Journal of Medical Sciences
http://journals.tubitak.gov.tr/medical/

Research Article

Turk J Med Sci
(2016) 46: 1838-1845
© TÜBİTAK
doi:10.3906/sag-1511-137

The factors affecting survival in patients with bronchiectasis
Fatma ÇİFTCİ*, Elif ŞEN, Sevgi Behiye SARYAL, Zeynep Pınar ÖNEN, Banu GÜLBAY,
Öznur YILDIZ, Turan ACICAN, Gülseren KARABIYIKOĞLU
Department of Chest Disease, Faculty of Medicine, Ankara University, Ankara, Turkey
Received: 23.112015

Accepted/Published Online: 27.03.2016

Final Version: 20.12.2016

Background/aim: There is limited information about the rate and modifiers of mortality in noncystic fibrosis bronchiectasis.
Materials and methods: This study enrolled a total of 56 bronchiectasis patients. Patients’ body mass index, smoking habit, previous
therapies, comorbid disorders, history of vaccination, bronchiectasis type and radiological extent, arterial blood gas analysis, respiratory
function tests, and laboratory results were recorded.
Results: After a follow-up of 65.38 ± 18.62 months the overall mortality rate was 35.7%. The mean survival duration was 46.42 ± 8.25
months. Advanced age significantly increased mortality (HR: 2.031; CI: 0.991–4.072, P = 0.035). A significant correlation was found
between mortality rate and the partial oxygen pressure level (HR: 0.886 (CI: 0.817–0.960); P = 0.039). Pulmonary artery pressure
was directly proportional to mortality rate (HR: 9.015 (CI: 3.272–94.036); P = 0.03). There was also a significant correlation between
Pseudomonas aeruginosa proliferation in sputum and mortality (HR: 7.014 (CI: 2.812–17.962); P = 0.00). Comorbidities increased
mortality (HR: 1.984 (CI: 0.972–2.996); P = 0.04).
Conclusion: Bronchiectasis is a disease with high mortality. Advanced age, comorbid conditions, reduced partial oxygen pressure,
pulmonary hypertension, and Pseudomonas aeruginosa proliferation in sputum increase its mortality rate.
Key words: Bronchiectasis survival, mortality, Pseudomonas aeruginosa

1.Introduction
Bronchiectasis is a rare disorder originating from
irreversible dilatation of segmental and subsegmental
airways as an abnormal and continuous distortion of
one or more conductive bronchi or airways (1). Injured
airways give rise to recurrent bacterial infections that
become chronic in some cases. The inflammatory response
in the host leads to tissue injury, which causes a vicious
cycle. It is unclear why some cases rapidly progress despite
the slow nature of progression in the majority of cases
(2). Prediction of the mortality rate of bronchiectasis is
very challenging owing to the difficulty in estimating the
disease’s exact prevalence and the scarcity of descriptive
studies so far reported. Moreover, risk factors for mortality
are yet to be clearly defined (3). The estimated annual
incidence of noncystic fibrosis bronchiectasis (NCFB)
has been reported as 1.3/1000, and it tends to be higher in
regions with low socioeconomic level (4).
It is currently unknown how radiological extent and
clinical signs of the disease or other factors affect mortality
rate although some domestic and foreign studies have
* Correspondence: fciftci@ankara.edu.tr
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been previously published on this subject (5,6). Although
a number of studies have linked the disease extent in high
resolution computed tomography (HRCT) to mortality
and some others have even developed an index combining
HRCT findings and a number of other parameters, an
association between the number of involved lobes or
segments and disease severity was rejected by some other
studies (7–9).
Determination of individuals at risk for future
mortality is central to clinical management of this disorder.
An increasing number of clinical trials of inhaled and oral
therapies are ongoing in bronchiectasis (10–13), and there
is a growing need to define which patients are most likely
to benefit from new treatments.
Determining potential factors affecting mortality and
thus estimating certain groups with higher mortality could
theoretically allow therapies to target patients who are
most likely to benefit from them.
This study therefore grouped bronchiectasis patients
into survivor and deceased groups after a follow-up of
almost 8 years to determine factors affecting mortality.
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2. Materials and methods
2.1. Patients and clinical evaluation
This retrospective cohort study enrolled a total of 56
patients (27 men, 29 women) who were diagnosed with
bronchiectasis at the outpatient clinic of a university hospital
between January 2000 and December 2004. The study was
approved by Ankara University School of Medicine Clinical
Researches Ethical Committee (No: 23-052014).
All patients had bronchiectasis confirmed by a HRCT
scan; patients with a definitive diagnosis of cystic fibrosis
were excluded. An informed consent was obtained from
each subject. The subjects were clinically and radiologically
followed until December 2008. During the first visit, the
subjects’ age, sex, body mass index, smoking habit, previous
therapies, comorbid disorders, history of tuberculosis,
history of regular vaccination (influenza and pneumococcus
vaccines), previous thoracic surgery or resection history,
bronchiectasis-related complications (respiratory failure,
cor pulmonale, empyema, metastatic abscess, amyloidosis,
hemoptysis), and types, dosages, and durations of
medications (antibiotics, inhaled corticosteroids, inhaled
long acting beta-2 agonists, inhaled anticholinergics, and
oral N-acetyl cysteine) were recorded. The etiological
factors for developing bronchiectasis were questioned.
Arterial blood gas analysis, respiratory function tests, and
laboratory blood tests (hemogram, albumin, total protein,
erythrocyte sedimentation rate, C-reactive protein level)
were performed. The bacteriological examinations were
performed from early-morning sputum samples.
Type (cystic, cylindrical, or varicose) and localization
of bronchiectasis were determined according to thoracic
HRCT. The radiological extent of the disease was determined
using the Thoracic HRCT scale (14). In this scale, a
normal radiological examination was assigned 0 points,
bronchiectasis at one or less bronchopulmonary segment 1
point, bronchiectasis at more than one bronchopulmonary
segment 2 points, and diffuse bronchiectasis 3 points.
The Charlson Comorbidity Index was used to calculate
the comorbidity scores and the 10-year survival rate (15).
During the follow-up period the number of exacerbations,
results of sputum cultures sampled during the exacerbations,
and the number of hospitalizations during follow-up were
recorded. An exacerbation was defined as an increase in
dyspnea and the amount or purulence of sputum (16).
Pulmonary hypertension was diagnosed on the
basis of clinical examination, radiological imaging, and
Doppler echocardiography in patients with clinical signs
of cor pulmonale. Subjects with a partial oxygen pressure
(PaO2) below 60 mmHg in arterial blood gas analysis were
considered as having hypoxemic (Type 1) respiratory failure,
and those with a partial carbon dioxide pressure (PaCO2)
over 45 mmHg as having hypercapnic (Type 2) respiratory
failure. Patients not attending planned follow-up visits were
contacted by telephone and information about their survival
was obtained.

The factors associated with survival in a period of 8 years
were evaluated in December 2008 by comparing the data of
the survivors and the deceased patients among the subjects
diagnosed between 2000 and 2004.
2.2. Statistical analysis
Statistical analysis was performed using SPSS, version
20.0 (SPSS Inc., Chicago, IL, USA). Descriptive data
were presented as mean ± standard deviation or number
(percentage). Student’s t-test and the chi-square test were
used to compare continuous variables and categorical
variables, respectively. Kaplan–Meier survival analysis
was used to determine the survival status. The log-rank
test was used to test differences in the cumulative survival
curves. Cox proportional hazard model analysis was used
to determine the relative mortality risks of different factors.
Univariate analysis was used to determine individual
variables predicting mortality; multivariate analysis was
used to determine independent variables predicting
mortality. Significance level was set at P < 0.05.
3. Results
The baseline demographic characteristics of the 56
bronchiectasis patients are presented in Table 1.
Table 1. General demographics of the bronchiectasis group.
Variable
Subjects, n

56

Age, years

60.54 ± 12.43

Male

27 (48.2)

BMI, kg/m2

28.45 ± 6.27

Smoking history, pack-years

27.12 ± 12.88

Previous tuberculosis

15 (26.8)

Sputum culture positivity

21 (37.2)

Bronchiectasis types
Cylindrical

17 (30)

Varicose

24 (43)

Cystic

15 (27)

PaO2, mmHg

56.42 ± 11.2

PaCO2, mmHg

44.98 ± 10.04

FEV1, % predicted

44.78 ± 15.22

FVC, % predicted

58.73 ± 17.37

FEV1/FVC,%

65.79 ± 11.74

TLC, % predicted

89.4 ± 14.5

PAPs

38.71 ± 13.29

Hematocrit, mg/dL

43.2 ± 5.26

CRP, mg/L

16.53 ± 13.47

ESR, h

31.41 ± 12.59

Data are presented as number (%) or mean ± SD. BMI: Body mass index;
PaO2: Partial oxygen pressure; PaCO2: Partial carbon dioxide pressure;
FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity;
TLC: Total lung capacity; CRP: C-reactive protein; ESR: Erythrocyte
sedimentation rate, PAPs: Pulmonary artery systolic pressure
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The mean age of the study population was 60.54 ± 12.43
years. Twenty-seven (48%) men and 29 (52%) women
were included. The mean follow-up duration was 65.38
± 18.62 months. The mortality rate was 35.7% and the
mean survival time was 46.42 ± 8.25 months. Seventeen
(30.3%) subjects were current smokers, 23 (41.1%) were
nonsmokers, and 16 (28.6%) were former smokers. At the
first visit, the information was obtained that five (9%) of the
patients had been regularly vaccinated against influenza
and 12 (21%) had been vaccinated against Streptococcus
pneumoniae with polyvalent vaccine at least once in their
lifetime after being diagnosed. At every visit all patients
with bronchiectasis were advised to get influenza and
pneumococcal vaccinations. In 2008 the information
was obtained that 22 (39.3%) patients had been regularly
vaccinated against influenza, 20 (35.7%) patients had been
irregularly vaccinated against influenza, and 14 (25%)
patients had never been vaccinated against influenza. At
the same date it was also noted that 25 (44.6%) patients
had been vaccinated against pneumococcal disease within
5 years. The etiology of bronchiectasis was unclear in 24
(43%) patients, while it was lung tuberculosis in 11 (20%)
patients, nontuberculous infections in 19 (34%) patients,
and alpha-1 antitrypsin deficiency in 2 (3%) patients.
As for complications of bronchiectasis, only a 58-yearold woman had been operated on with lobectomy for
recurrent hemoptysis; and she died in the sixth year of
follow-up. The analysis of the microbiological proliferation
in the sputum cultures revealed Pseudomonas aeruginosa
proliferation in 8 (14%) subjects, Haemophilus influenzae
in 5 (9%), Streptococcus pneumoniae in 4 (7%), Klebsiella
pneumoniae in 3 (5%), and Stenotrophomonas maltophilia

in 1 (2%). The most commonly observed comorbidities
in descending order were hypertension (n = 19; 33%),
diabetes mellitus (n = 12; 21%), and coronary artery
disease (n = 9; 16%).
The cumulative survival plot of the bronchiectasis
cases is shown in Figure 1.
Twenty (35.7%) patients died by the end of the study. The
patients with bronchiectasis were categorized into survivor
and deceased groups to compare their characteristics
(Table 2). The two groups were similar in terms of gender
distribution. The mean age of the survivors was 56.05 ±
10.22 and the deceased patients was 66.18 ± 10.37 years
(P = 0.0087). There was no significant difference between
the two groups with respect to smoking status, vaccination
rates with both vaccines, and initial therapies. At the start
of the study hypoxemic respiratory failure was detected
in 10 (50%) subjects in the deceased group and 16 (44%)
subjects in the survivor group (P > 0.05). Arterial blood
gas analysis at the final visit revealed a lower PaO2 level in
the deceased group (P = 0.041). The deceased group had
a significantly higher rate of cor pulmonale (P = 0.036).
The two groups did not significantly differ with regard to
PaCO2 level at the first and final visits. There were also no
significant differences between the respiratory function
tests of the two groups. The survivor and deceased groups
did not significantly differ with respect to the radiologic
extent of the disease. The rate of bacterial culture positivity
was significantly higher in the deceased group (P = 0.046).
Eight subjects, all of whom were in the deceased group,
had Pseudomonas aeruginosa proliferation in sputum
samples. The deceased group had a significantly higher
rate of Pseudomonas proliferation (P = 0.043).

Survival function
1.0

Cum survival

0.9

0.8

0.7

0.6
Follow-up time
Figure 1. The Kaplan–Meier cumulative survival plot demonstrating
survival rates of subjects with bronchiectasis during 8-year follow up.
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Table 2. General characteristics of the survivor and deceased groups.
Variable

Deceased patients

Survivors

P value

Subjects, n

20 (35.7)

36 (64.3)

Age

66.18 ± 10.37

56.05 ± 10.22

0.0087

Male

11 (55)

16 (44)

>0.05

6 (30)

11 (30.5)

>0.05

Smoking status
Current smoker
Former smoker

6 (30)

10 (27.7)

>0.05

Nonsmoker

8 (40)

15 (41.7)

>0.05

9 (45)

13 (36.1)

>0.05

Vaccination
Influenza vaccinated regularly
Influenza vaccinated irregularly

6 (30)

14 (38.9)

>0.05

Influenza nonvaccinated

5 (25)

9 (25)

>0.05

Pneumococcal vaccination

8 (40)

17 (47.2)

>0.05

Treatment
Inhaled long acting beta-2 agonists

14 (70)

21 (58.3)

>0.05

Inhaled anticholinergics

11 (60)

17 (47.2)

>0.05

Inhaled steroids

6 (30)

11 (30.5)

>0.05

Oral N-acetylcysteine

17 (85)

28 (77.7)

>0.05

Sputum bacterial culture results
Pseudomonas aeruginosa

8 (40)

0

0.043

Haemophilus influenzae

3 (15)

2 (5.5)

>0.05

Streptococcus pneumoniae

3 (15)

1 (2.8)

>0.05

Klebsiella pneumoniae

2 (10)

1 (2.8)

>0.05

Stenotrophomonas maltophilia
PaO2, mmHg

0

1 (2.8)

>0.05

55.9 ± 12.08

56.7 ± 10.8

>0.05

PaCO2, mmHg

45.7 ± 10.2

44.5 ± 10.1

>0.05

FEV1, % predicted

46.05 ± 14.09

44.15 ± 15.93

>0.05

Hypoxemic respiratory failure

10 (50)

16 (44)

>0.05

Cor pulmonale

8 (40)

4 (11.1)

0.036

Charlson estimated 10-year survival %

46.15 ± 33.83

76.52 ± 23.56

0.0065

Charlson comorbidity index

4.10 ± 1.22

2.15 ± 1.26

0.0072

No. of hospitalizations during follow up

3.10 ± 1.71

2.83 ± 0.47

>0.05

5 (25)

6 (16.7)

>0.05

Location of bronchiectasis
Right upper lobe
Right middle lobe

8 (40)

12 (33.3)

>0.05

Right lower lobe

9 (45)

17 (47.2)

>0.05

Left upper lobe

5 (25)

8 (22.2)

>0.05

Lingula

6 (30)

10 (27.8)

>0.05

10 (50)

19 (52.7)

>0.05

Bronchiectasis in one or less bronchopulmonary segment

Left lower lobe

5 (25.0)

9 (25.0)

>0.05

Bronchiectasis in more than one bronchopulmonary segment

9 (45.0)

15 (41.7)

>0.05

Diffuse bronchiectasis

6 (30.0)

12 (33.3)

>0.05

Data are presented as number (%) or mean ± SD. PaO2: Partial oxygen pressure; PaCO2: Partial carbon dioxide pressure; FEV1: Forced
expiratory volume in 1 s
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A significant correlation was found between the
radiological extent of the bronchiectasis and the presence
of respiratory failure (P = 0.041). Similarly, the extent of
bronchiectasis was significantly greater in the subjects
with cor pulmonale than in those without (P = 0.039).
Cox proportional hazard model analysis was used to
determine relative risk of death with different variables
(Table 3). According to that analysis, advanced age (HR:
2.031 (CI: 0.991–4.072); P = 0.035), final PaO2 level (HR:
0.886 (CI: 0.817–0.960); P = 0.039), systolic pulmonary
artery pressure (HR: 9.015 (CI: 3.272–94.036); P = 0.03),
and Pseudomonas aeruginosa proliferation (HR: 7.014 (CI:
2.812–17.962; P = 0.00) significantly increased the risk of
death, whereas microorganisms other than Pseudomonas
species and disease duration did not. As shown by a
Kaplan–Meier cumulative survival plot, the survival rate

was significantly lower in patients with Pseudomonas
proliferation than in those without (Figure 2). The
Charlson Comorbidity Index and Charlson estimated 10year survival percentage significantly increased the risk of
death (HR: 1.984 (CI: 0.972–2.996); P = 0.04).
4. Discussion
There is limited information about the mortality rate of
bronchiectasis, which is considered an orphan disease
despite being commonly encountered. In the present study,
age, comorbid conditions, PaO2 level, presence of cor
pulmonale, and bacterial infections significantly increased
the mortality rate associated with the disease, which was
found to be 35.7% during a follow-up time of 18 to 96
months. Onen et al. reported a mortality rate of 16.3%
after a median follow-up of 4 years (17). In that study the

Table 3. Cox proportional hazard analysis of significant predictors of mortality.
HR

95% CI

P value

Age, years

2.031

0.991–4.072

0.035

PaO2, mmHg

0.886

0.817–0.960

0.03

PAPs

9.015

3.272–94.036

0.03

Pseudomonas aeruginosa proliferation

7.014

2.812–17.962

0.000

CCI

1.984

0.972–2.996

0.04

CI: confidence interval, PaO2: Partial oxygen pressure, PAPs: Pulmonary artery systolic pressure, CCI: Charlson comorbidity index
Survival function
1.0

Pseudomonas proliferation negative
Pseudomonas proliferation positive

Cum survival

0.8

0.6
0.4
0.2

0.0
Follow-up time
Figure 2. The Kaplan–Meier cumulative survival plot demonstrating significantly higher mortality in patients
with Pseudomonas proliferation in sputum culture.
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Table 4. Comparison of the first and final visit characteristics of the study subjects.
First visit

Final visit

Variable

Deceased patients

Survivors

Subjects, n

20

36

PaO2, mmHg

55.9 ± 12.08

56.7 ± 10.8

PaCO2, mmHg

45.7 ± 10.2

FEV1, % predicted

P value

Deceased patients

Survivors

P value

20

36

>0.05

43.25 ± 8.14

55.18 ± 12.3

0.041

44.5 ± 10.1

>0.05

47.12 ± 8.21

45.16 ± 10.03

>0.05

44.15 ± 15.93

46.05 ± 14.09

>0.05

43.17 ± 13.2

47.14 ± 9.05

>0.05

FVC, % predicted

49.17 ± 12.16

52.19 ± 13.27

>0.05

45.28 ± 10.15

50.17 ± 11.12

>0.05

FEV1/FVC, %

62.12 ± 18.13

66.31 ± 10.21

>0.05

65.16 ± 20.17

64.16 ± 16.03

>0.05

6-MWT, m

410.25 ± 65.32

540.18 ± 62.24

>0.05

320.14 ± 48.11

527.37 ± 85.16

0.045

PAPs, mmHg

44.32 ± 8.27

29.41 ± 5.19

0.037

48.16 ± 6.12

31.19 ± 5.27

0.033

Data are presented as mean ± SD. PaO2: Partial oxygen pressure, PaCO2: Partial carbon dioxide pressure, FEV1: Forced expiratory
volume in 1 s, FVC: Forced vital capacity, 6MWT: 6-min walking test, PAPs: Pulmonary artery systolic pressure

female-to-male ratio, body mass index, and PaO2 levels
were greater than in our study population. Goemminne
et al. reported an overall mortality rate of 20.4% after a
median follow-up of 5.18 years (7). In that study, the age
range and the sex distribution of the patient population
were similar to in our study although the number of
subjects with COPD was significantly higher.
Not surprisingly, previous reports have reported a
higher mortality rate in the elderly. Dupont et al. reported
that mortality was increased more than twofold in patients
with bronchiectasis aged above 65 years (relative risk
[RR], 2.70; 95% confidence interval [CI], 1.15 to 6.29)
(18,19). Age > 65 years, comorbidities, and treatment
noncompliance may underlie an increased mortality rate
(20–22).
The number of vaccinated patients was quite low at
the start of our study. Moreover, during the follow-up,
vaccination rates remained low despite the patients having
been informed about vaccination and being advised to get
vaccinated. No significant correlation was found between
vaccination with influenza and pneumococcal vaccines
and overall mortality. In fact, we expected a mortality
reduction by lowering the rates of exacerbations, disease
complications, and the number of hospitalizations by
vaccination. The failure to detect such a finding may be a
result of the small sample size.
Smoking status did not affect mortality in our study.
Loebinger et al. showed that the mortality rate was not
increased in smokers (RR: 1.78 (CI: 0.87 – 3.63), P = 0.120)
(2). Onen et al. reported that smoking history and the
presence of COPD as a comorbid condition did not have
an influence on mortality from bronchiectasis (17).

Bacterial proliferation occurred in 21 subjects from
the sputum samples taken during the first visit. As recently
reported by others, the most frequently proliferated
bacterial pathogen was Pseudomonas aeruginosa in the
present study (23). The culprit bacteria were Pseudomonas
aeruginosa species in eight subjects, all in the deceased
group. The mortality rate was increased by the presence
of bacterial colonization. Particularly, the rate of
Pseudomonas aeruginosa infection was significantly higher
in the deceased group. It is already known that patients
with bronchiectasis are more susceptible to Pseudomonas
aeruginosa infection due to impaired airway mucus
clearance as a result of chronic bronchial dilatation. Being
one of the most common agents of infection, Pseudomonas
species adversely affect the immune system. Inflammation
causes increased interleukin 8 synthesis, which in turn
interacts with chemokine receptor CXCR1 to attract
neutrophils to the site of inflammation. Proteases secreted
by pseudomonas impair CXCR1’s functions and interfere
with neutrophil aggregation, events that ultimately
prevent bacterial killing. The increased rate of isolation of
Pseudomonas in patients with bronchiectasis is associated
with worsened disease severity, airway obstruction, and
quality of life (24–26).
Our data showed that there was no significant
relationship between radiological extent of the disease
and mortality. We also did not find any significant
correlation between the radiological extent of the disease
and respiratory functions or bacterial proliferation rates.
Chalmers et al. failed to show any significant correlation
between the radiological extent and mortality (8).
Nevertheless, in that study the radiological severity
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of bronchiectasis was assessed using a modified Reiff
score (27) that takes into account the number of lobes
involved and the degree of bronchial dilatation. That study
demonstrated a significant relationship between the Reiff
score and hospital admissions (8,27). This suggests that
not the number of affected lobes alone, but other factors
such as bronchial dilatation severity may be important
points for radiological assessment.
Our study also importantly showed that although the
radiological extent of the disease was not directly related
to survival, it indirectly increased mortality by worsening
respiratory failure and cor pulmonale.
The patient population in the present study had a
strikingly higher comorbidity rate. Charlson comorbidity
indexes and estimated 10-year survival rates as determined
by comorbidity analysis showed a significant correlation
with mortality. Considering the impact of comorbidities
on the prognosis, progression, and mortality of the
disease, it may be hypothesized that bronchiectasis itself
may create a systemic inflammatory state (27). Monitoring
and treatment of accompanying comorbid conditions may
contribute to reduce the mortality rate of bronchiectasis.
The deceased group was more often diagnosed with cor
pulmonale compared to the survivors. The pathophysiology
of pulmonary hypertension in chronic lung disease
is multifactorial and includes hypoxic pulmonary
vasoconstriction, pulmonary vascular remodeling, small
vessel destruction, and fibrosis. Pulmonary hypertension
in bronchiectasis is typically of mild-to-moderate

severity. Development of pulmonary hypertension is a
poor prognostic sign in chronic lung disorders. In severe
bronchiectasis perfusion is impaired secondary to capillary
bed injury and left-to-right shunting, which impair cardiac
functions and pulmonary gas exchange. This may explain
why pulmonary hypertension is a poor prognostic sign in
bronchiectasis.
In our study the initial PaO2 level was not a prognostic
factor. Our hypotheses for this finding are the following.
We only measured resting PaO2 levels of our patients.
However, they may have exercise hypoxemia leading to
pulmonary hypertension. The latter can also originate
from fibrosis that develops in secondary bronchiectasis
due to recurrent infections. Hence, there is a mixed type
airflow limitation. PaO2 level tended to be lower during
exacerbations of bronchiectasis, which contributes to the
progress of pulmonary hypertension. A reduced PaO2 level
at the final visit significantly increased mortality.
The main limitation of our study is its small sample size.
This caused the number of factors affecting mortality to
be small among the overall sample, reducing the statistical
power and producing weaker statistical correlations
between the study parameters.
In conclusion, this analysis revealed a bronchiectasis
mortality rate of 35.7% during a follow-up of almost 8
years. The variables related to increased mortality were
advanced age, a high Charlson comorbidity score, PaO2,
cor pulmonale, and Pseudomonas proliferation.
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